MANE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	201.33M	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-
Book/sh	-0.24	P/C	-	EPS next 5Y	-	ROE	-	52W High	- -	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	- -	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	-	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	11.77	EPS Q/Q	-	SMA20	-	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-	Rel Volume	-	Prev Close	-
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-	Avg Volume	-	Price	-
IPO	-	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	0	Change	-

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Veradermics Inc

Upgrade your FINVIZ experience